Generic Name and Formulations:
Betamethasone (as dipropionate) 0.05%, clotrimazole 1%; crm; lotion.
Merck & Co., Inc.
Indications for LOTRISONE:
Tinea pedis, t. cruris, t. corporis.
T. cruris, t. corporis: apply thin film twice daily for 1 week; max 2 weeks. T. pedis: apply sufficient amount twice daily for 2 weeks; max 4 weeks. Max 45g (crm), 45mL (lotion) per week. Do not occlude.
<17yrs: not recommended.
Avoid eyes. Do not use for diaper dermatitis. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Thinning skin. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Steroid + azole antifungal.
Rash, edema, secondary infections; HPA axis suppression (esp. in children), skin atrophy.
Crm—15g, 45g; Lotion—30mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Combination Immunotherapy Shown To Be Clinically Meaningful in Melanoma Metastatic to the Brain
- Large, Upfront Assay Sped Genomic Results, Targeted Treatments in NSCLC
- Future Perspectives for Targeted Therapy in NSCLC
- Pathologic Tumor Analysis Leads Progress in the Understanding and Treatment of NSCLC
- MET Inhibitor Shows Antitumor Activity in Advanced NSCLC